US 11253572
Use of a VEGF antagonist to treat angiogenic eye disorders
granted A61KA61K2039/505A61K38/179
Quick answer
US patent 11253572 (Use of a VEGF antagonist to treat angiogenic eye disorders) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61K38/179, A61K9/0048, A61P